Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.40 |
| ▸ | GRM5 | P41594 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.31 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
| ▸ | LOX | P28300 | 1/20 | 0.30 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.30 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24983084 | 0.87 | LRRK2 (0.44) | GRM5HDAC6LRRK2 | |
| SCHEMBL27231784 | 0.87 | LRRK2 (0.44) | GRM5HDAC6LRRK2 | |
| SCHEMBL30849531 | 0.87 | LRRK2 (0.44) | GRM5HDAC6LRRK2 | |
| SCHEMBL24983232 | 0.87 | LRRK2 (0.44) | GRM5HDAC6LRRK2 | |
| SCHEMBL30849530 | 0.87 | LRRK2 (0.44) | GRM5HDAC6LRRK2 | |
| SCHEMBL22576465 | 0.83 | MALT1 (0.39) | KMOHDAC6MALT1ALOX5APFEN1 | |
| SCHEMBL15577842 | 0.83 | HDAC6 (0.45) | GRM5HDAC6LRRK2SYK | |
| SCHEMBL3411667 | 0.81 | NUDT1 (0.44) | KMOALOX5APFEN1LOXLOXL2 | |
| SCHEMBL19510752 | 0.80 | LOX (0.44) | KMOGRM5LRRK2MALT1ALOX5AP | |
| SCHEMBL22895345 | 0.80 | LOX (0.47) | KMOLRRK2MALT1ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360104-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2024-10-31 | — | — | US | disclosed |
| US-20240124406-A1 | INHIBITORS OF TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2024-04-18 | — | — | US | disclosed |
| EP-4330253-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-116761795-A | Inhibitors of Transcription Enhancement Associated Domain (TEAD) and uses thereof | 达纳-法伯癌症研究所股份有限公司 | 2023-09-15 | — | — | CN | disclosed |
| EP-4164752-A1 | INHIBITORS OF TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2023-04-19 | — | — | EP | disclosed |
| WO-2022232088-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-11-03 | — | — | WO | disclosed |
| US-20200325154-A1 | ANTIBACTERIAL BIAROMATIC DERIVATIVES WITH OXETANE-3-YLOXY SUBSTITUTION | ACTELION PHARMACEUTICALS LTD (CH) | 2020-10-15 | — | — | US | disclosed |
| EP-3442970-A1 | ANTIBACTERIAL BIAROMATIC DERIVATIVES WITH OXETANE-3-YLOXY SUBSTITUTION | Idorsia Pharmaceuticals Ltd (CH) | 2019-02-20 | — | — | EP | disclosed |
| WO-2017179002-A1 | ANTIBACTERIAL BIAROMATIC DERIVATIVES WITH OXETANE-3-YLOXY SUBSTITUTION | ACTELION PHARMACEUTICALS LTD (CH) | 2017-10-19 | — | — | WO | disclosed |
| US-20140243290-A1 | Aminopyrimidines as SYK Inhibitors | ALTMAN MICHAEL D (US) | 2014-08-28 | — | — | US | disclosed |
| US-8759366-B2 | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8551984-B2 | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2012-11-01 | — | — | US | disclosed |
| EP-2513098-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-10-06 | — | — | US | disclosed |
| WO-2011075515-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | KMO 108/4885GRM5 2816/4885HDAC6 3782/4885 |
| US-20240124406-A1 | INHIBITORS OF TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) AND USES THEREOF | TEAD1, TEAD2, TEAD4 | KMO 3756/4885GRM5 4083/4885HDAC6 973/4885 |
| US-20240360104-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATED DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD4, TEAD1, TEAD2 | KMO 4043/4885GRM5 4675/4885HDAC6 1481/4885 |
| US-20200325154-A1 | ANTIBACTERIAL BIAROMATIC DERIVATIVES WITH OXETANE-3-YLOXY SUBSTITUTION | MT-CO3, UQCRC1, MT-ND3 | KMO 1210/4885GRM5 4774/4885HDAC6 2050/4885 |
| US-20140243290-A1 | Aminopyrimidines as SYK Inhibitors | SYK, BTK, LCK | KMO 108/4885GRM5 2816/4885HDAC6 3782/4885 |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | KMO 108/4885GRM5 2816/4885HDAC6 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.